Atom Investors LP Takes $5.80 Million Position in Kodiak Sciences Inc. $KOD

Atom Investors LP purchased a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 207,495 shares of the company’s stock, valued at approximately $5,802,000. Atom Investors LP owned 0.39% of Kodiak Sciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC boosted its holdings in shares of Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at $29,000. Headlands Technologies LLC boosted its holdings in shares of Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after acquiring an additional 5,815 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at $72,000. Finally, Strs Ohio acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at $87,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Price Performance

KOD opened at $32.94 on Wednesday. Kodiak Sciences Inc. has a 12 month low of $3.43 and a 12 month high of $47.84. The stock has a market cap of $2.06 billion, a P/E ratio of -7.90 and a beta of 2.21. The stock’s 50 day moving average price is $39.01 and its 200 day moving average price is $30.80.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Thursday, May 7th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.01). Equities analysts anticipate that Kodiak Sciences Inc. will post -3.89 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on KOD shares. HC Wainwright reissued a “buy” rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a report on Friday, March 27th. Wall Street Zen upgraded Kodiak Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Chardan Capital upgraded Kodiak Sciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $14.00 to $61.00 in a research report on Monday, May 11th. Finally, UBS Group raised their target price on Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $42.14.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.